The blood-brain-barrier serves to encapsulate and protect the central nervous system, but it also presents a major barricade to therapeutic drug delivery. Poor penetration is the most common hurdle to translating a promising experimental therapy that uses invasive delivery methods to a clinically useful application. In the last 10 years, intranasal delivery of various therapeutic compounds including small chemicals, large proteins, and even stem cells has proven to be very effective in bypassing the blood-brain-barrier and has led to some important advances in translational research for stroke and other neurological diseases. The proposed book will bring together reports from various labs around the world who have had successes in pre-clinical studies of intranasal therapies for various diseases including adult and perinatal stroke, Alzheimer's, Parkinson's, and others.
The blood-brain-barrier prevented harmful materials entering the brain and in the meantime is a barricade to therapeutic drug delivery. Intranasal drug delivery to circumvent blood-brain-barrier was developed in the past, to take advantages of a secret passage from the olfactory epithelium into the brain—bypassing the tight junctions that encapsulated the brain from blood circulation. This timely publication of Therapeutic Intranasal Delivery for Stroke and Neurological Disorders presented some of the latest advances in intranasal delivery research, including transnasal hypothermia induction, stem cell intranasal transplantation, intranasal drug delivery in ischemic and hemorrhagic models, intranasal peptides delivery, intranasal tPA application in adults and children.
Editors Jun Chen, Jian Wang, Ling Wei and John Zhang are professors from University of Pittsburgh, Johns Hopkins University, Emory University and Loma Linda University in USA.